Will A CV Warning On Meridia Alter FDA Views On Obesity Drugs?

The FDA's cardiovascular safety warning on Abbott's obesity drug Meridia (sibutramine) - which was issued in light of early results from a 10,000 patient strong outcomes study - could mean higher regulatory risk for up-and-coming obesity drugs

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet